{"nctId":"NCT02449889","briefTitle":"A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation","startDateStruct":{"date":"2016-04"},"conditions":["Infertility"],"count":176,"armGroups":[{"label":"HP-hCG IM","type":"EXPERIMENTAL","interventionNames":["Drug: highly purified human chorionic gonadotropin"]},{"label":"HP-hCG SC","type":"EXPERIMENTAL","interventionNames":["Drug: highly purified human chorionic gonadotropin"]},{"label":"rhCG","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: recombinant human chorionic gonadotropin"]}],"interventions":[{"name":"highly purified human chorionic gonadotropin","otherNames":["CHORAPUR","BREVACTID"]},{"name":"recombinant human chorionic gonadotropin","otherNames":["OVIDREL","OVITRELLE"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pre-menopausal females between the ages of 18 and 39 years\n* Documented history of infertility\n* Body mass index (BMI) between 17.5 and 32.0 kg/m2\n* Regular menstrual cycles\n\nExclusion Criteria:\n\n* Known endometriosis stage III and IV\n* Known polycystic ovarian syndrome (PCOS)\n* History of recurrent miscarriage\n* History of more than three previous controlled ovarian stimulation cycles","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","maximumAge":"39 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Oocytes Retrieved","description":"Oocyte retrieval took place 36 h (±2h) after hCG administration. At oocyte retrieval the number of oocytes retrieved was recorded.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"4.6"},{"groupId":"OG001","value":"7.3","spread":"4.8"},{"groupId":"OG002","value":"6.6","spread":"4.1"}]}]}]},{"type":"SECONDARY","title":"Number of Metaphase II (MII) Oocytes","description":"Only applicable for insemination using intracytoplasmic sperm injection (ICSI). The MII oocytes were counted prior to insemination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"3.7"},{"groupId":"OG001","value":"6.2","spread":"3.5"},{"groupId":"OG002","value":"5.6","spread":"3.3"}]}]}]},{"type":"SECONDARY","title":"Number of Fertilized (2 Pronuclei (2PN)) Oocytes","description":"Fertilization was assessed by counting the number of pronuclei, which was recorded as 0, 1, 2 or \\>2. Correct fertilization was defined as oocytes with 2PN.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":"3.3"},{"groupId":"OG001","value":"4.7","spread":"3.4"},{"groupId":"OG002","value":"4.2","spread":"2.7"}]}]}]},{"type":"SECONDARY","title":"Positive β Unit of Human Chorionic Gonadotropin (βhCG) Rate","description":"Defined as percentage of subjects with positive beta hCG. A positive β hCG was confirmed by a blood test obtained 13-15 days after transfer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"37.9","spread":null},{"groupId":"OG002","value":"36.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Pregnancy Rate","description":"Defined as percentage of subjects with clinical pregnancy. Clinical pregnancy was defined as at least one gestational sac 5-6 weeks after transfer.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.6","spread":null},{"groupId":"OG001","value":"27.6","spread":null},{"groupId":"OG002","value":"31.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Adverse Events (AEs)","description":"The number of treatment-emergent AEs (TEAEs) in each treatment group will be presented.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"25","spread":null},{"groupId":"OG002","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Intensity of AEs","description":"The intensity of an TEAE would be classified using the following 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity \\[disturbing\\]) or severe (inability to work or perform usual activities \\[unacceptable\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":58},"commonTop":["Biochemical pregnancy","Haemorrhage in pregnancy","Pelvic pain","Nausea","Headache"]}}}